Best Traditional Pharmaceuticals Companies in New York, United States
The 49 best Traditional Pharmaceuticals companies in New York, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Vertice Pharma.
Our analysis of 50 Traditional Pharmaceuticals companies
$3.2b in tracked funding; 51% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2016.
Ranked: Best Traditional Pharmaceuticals companies in New York
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Vertice Pharma Acquire and develop branded and generic specialty pharmaceuticals | $300M | 128 mo ago | Late Stage | — | 2015 | — | — | — |
| 2 | Petros Manufacturer of men's health therapeutic products | $40M | 37 mo ago | Public | John David Shulman CEO | 2020 | WordPressMySQLPHP+23 | — | — |
| 3 | Edenbridge Pharmaceuticals Developer of branded and generic specialty pharmaceutical products | $30M | — | Acquired | Ryan Collins Co-Founder & CEO | 2008 | NginxOpenRestyHSTS+1 | — | — |
| 4 | R & B Supply Chain Provider of pharmaceutical goods, machinery, equipment and supplies | $14M | 35 mo ago | Series B | Robert Caucci CEO | — | — | 151 patents Patents concentrated in transport & manufacturing processes | — |
| 5 | IpiNovyx Bio Manufacturer of drugs for the treatment of autoimmune and inflammatory diseases | $10M | 58 mo ago | Deadpooled | — | 2021 | — | — | — |
| 6 | Saptalis Pharmaceuticals Developer and manufacturer of niche generic and innovative pharmaceutical products | $10M | 117 mo ago | Series A | Polireddy Dondeti Co-Founder & CEO | 2015 | — | — | — |
| 7 | Aspargo Laboratories Develops oral suspension sprays | $8M | 44 mo ago | Series A | Michael Demurjian Founder and CEO of Aspargo Laboratories Inc. | 2019 | WordPressMySQLPHP+18 | 36 patents Smart oral medication dispensing devices with secure cartridges and wireless control | — |
| 8 | Pyros Pharma Pyros Pharmaceuticals is a specialty pharmaceutical company focused on developing and commercializing… | $6M | 52 mo ago | Acquired | — | 2017 | — | — | — |
| 9 | Equilibre Biopharmaceuticals Manufacturer of specialty drugs | $6M | 44 mo ago | Series A | Philip Barach CEO | 2020 | — | — | — |
| 10 | Cmtx Biotech Developer of small-molecule treatments for rare and pandemic diseases | $4M | 14 mo ago | Funding Raised | — | 2019 | — | — | — |
| 11 | Reliable 1 Laboratories Manufacturer of generic drugs | $2M | 38 mo ago | Seed | David Seltzer CEO | 2015 | Cart FunctionalitySquarespace CommerceSquarespace+12 | — | — |
| 12 | Applied Biological Laboratories Natural respiratory drugs for common illnesses, scientifically proven and effective | $1M | 83 mo ago | Series A | Michael Latefi Co-Founder and Operating Board Member | 2016 | — | — | — |
| 13 | Curist Manufacturer of generic drugs | $708K | 83 mo ago | Seed | Ethan Goldstein Founder & CEO | 2018 | Cart FunctionalityShopifySentry+26 | — | — |
| 14 | Redox Pharmaceuticals Developer of medicines for antiviral, antibacterial, and anti-inflammatory diseases | $123K | 199 mo ago | Deadpooled | — | 1980 | — | — | — |
| 15 | PregPrep Manufacturer of fertility focused formulations | $100K | 130 mo ago | Seed | Lara Oboler Co-Founder | 2008 | — | — | — |
| 16 | Pfizer Provider of pharmaceutical products for multiple disease treatments | — | 37 mo ago | Public | Sai Boddu Director | 1849 | DrupalApple iCloud MailPHP+25 | — | — |
Top 12 Traditional Pharmaceuticals companies in New York
#1
Funding Raised · Stony Brook, New York · founded 2019 · 6 employees$3.7Mraised▾
Developer of small-molecule treatments for rare and pandemic diseases. The company focuses on clinical-stage drug candidates, prioritizing proven safety and accelerated development. Its lead drug candidate has completed IND-enabling studies and human safety testing in other indications, expediting clinical trials and market approval. A seasoned management team with expertise in drug development, commercialization, licensing, and technology transfer guides the company's efforts. The company leverages its proprietary small-molecule technology to improve patient outcomes in the treatment of orphan diseases.
- May 2025Grant (prize money)$1.3M
- Feb 2025Grant (prize money)$1.3M
- Jul 2024Grant (prize money)$300K
- May 2023Grant (prize money)$376.8K
#2
Public · New York City, New York · founded 2020 · 24 employees$40Mraised▾
Manufacturer of men's health therapeutic products
- Jul 2023Post IPO$30M
- Dec 2021Post IPO$10M
#3
Series B · New York City, New York$13.5Mraised▾
Provider of pharmaceutical goods, machinery, equipment and supplies
#4
Late Stage · New York City, New York · founded 2015 · 45 employees$300Mraised▾
Vertice Pharma is a specialty pharmaceuticals company focused on improving patients health. Vertice Pharma develops, manufactures, markets, and distributes pharmaceutical products through its operating companies. Acquiring, manufacturing and distributing generic pharmaceutical products the main focus of their business. In November 2015, Vertice Pharma announced that it is acquiring VistaPharm, a specialized generics manufacturer of liquid and unit dosage pain medications for the hospital market, retail pharmacy and outpatient clinics.
- Nov 2015PE$300M
#5
Series A · New York City, New York · founded 2019 · 7 employees$8.2Mraised▾
Develops oral suspension sprays
- Dec 2022Series A$290K
- Oct 2020Series A$7.9M
#6
Series A · New York City, New York · founded 2020 · 13 employees$6Mraised▾
Manufacturer of specialty drugs
- Nov 2022Series A$6M
#7
Seed · Valley Stream, New York · founded 2015$2Mraised▾
Manufacturer of generic drugs. It also manufactures vitamins and nutritional supplements. Its products portfolio includes cough, allergies, pain relief, eye care, heartburn, skin problems, and lip care. It is focused on providing the best service possible and exceeding the level of expectations of its customers.
- May 2023Seed$2M
#8
Acquired · New York City, New York · founded 2017 · 35 employees$6.4Mraised▾
Pyros Pharmaceuticals is a specialty pharmaceutical company focused on developing treatments for rare diseases, particularly those affecting infants and young children. The company is driven by a mission to elevate the standard of care for infantile spasms and is committed to making a meaningful difference in the lives of patients and families.
- Apr 2022Series A$450K
- Aug 2020Series A$5.9M
#9
Deadpooled · West Nyack, New York · founded 2021 · 5 employees$10Mraised▾
Developer of immunoproteasome-modulating therapeutics platform designed to transform the treatment of autoimmune and inflammatory diseases. The company's platform helps in the creation of inhibitors to selectively target the immunoproteasome and modulate specific immune cell types, enabling patients to recover from autoimmune and inflammatory diseases and improve their health.
- Oct 2021Seed$10M
#10
Acquired · New York City, New York · founded 2008 · 23 employees$30Mraised▾
Edenbridge Pharmaceuticals is developing branded and generic specialty pharmaceutical products. The company claims that it has a product development pipeline that includes ANDAs, 505(b)(2)s & foreign filings. The Company offers bumetanide, carbidopa, ethacrynic acid, ivermectin, methenamine mandelate, and tinidazole tablets, opium tincture & prednisolone sodium phosphate oral solution.
- Conventional Debt$30M
#11
Series A · Hauppauge, New York · founded 2015 · 66 employees$9.5Mraised▾
Developer and manufacturer of niche generic and innovative pharmaceutical products. This company specializes in the development, manufacturing, and commercialization of liquid and semi-solid dosage forms. It utilizes both ANDA and 505(b)(2) regulatory pathways for product approval. The company possesses state-of-the-art facilities and a strong R&D focus. Its product portfolio includes both generic and branded medications. The company's manufacturing processes adhere to cGMP standards.
- Nov 2016Series A$6.5M
- Sep 2015Seed$3M
#12
Series A · Brooklyn, New York · founded 2016 · 10 employees$1.2Mraised▾
Natural respiratory drugs for common illnesses, scientifically proven and effective. The company researches, develops, and distributes natural drugs for respiratory illnesses like rhinovirus, influenza, and asthma. They offer alternatives to chemical drugs, focusing on bioactive molecules to fortify the respiratory system and prevent viral infections. Their over-the-counter drugs are scientifically proven safer and more effective than leading remedies. They address respiratory inflammation with natural ingredients. They are committed to providing safe and effective solutions for cough, cold, and sore throat. They are participating in meetings on new strategies to combat antimicrobial resistance. They are focused on developing natural, anti-viral formulations to treat and prevent respiratory infections.
- Sep 2019Grant (prize money)$224.4K
- May 2016Series A$1M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Traditional Pharmaceuticals coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Drug Discovery is moving in the United States
A read on the academic research around Drug Discovery — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 9,593 United States-affiliated papers.
- Harvard University331
- University of North Carolina at Chapel Hill232
- Purdue University West Lafayette200
- Cornell University172
- Stanford University170
- Computational biology126→901
- Small molecule41→351
- Chemical space26→319
- Virtual screening24→288
- Bioinformatics14→216
- Computational biology102→599
- Docking (animal)27→275
- Drug development27→259
- Virtual screening29→235
- In silico12→211
- Computational biology75→206
- Drug development47→176
- Bioinformatics18→102
- Data science20→89
- Disease13→78
Where drug discovery is researched across United States
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Who's filing drug discovery patents in the United States
United States drug discovery patent filing is accelerating — 762,525 filings from 8,000 assignees (2016–2025), led by UNIV California, Genentech, Bristol Myers Squibb; annual filings 69033→70331.
- UNIV California22029
- Genentech19677
- Bristol Myers Squibb19149
- Procter & Gamble16492
- Lilly ELI15535
- Pfizer15334
- Merck Sharp & Dohme14790
- Amgen14371
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.